The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

The European Commission has granted marketing authorization for Yeytuo (lenacapavir)—Gilead Sciences Inc.’s twice-yearly ...

Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 ...

Deborah Wafer, Executive Director of Public Affairs at Gilead Sciences, is working to address one of the most pressing health disparities in America: the gap between HIV risk and prevention access ...